<DOC>
	<DOC>NCT00692263</DOC>
	<brief_summary>Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours. It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol</brief_summary>
	<brief_title>The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Healthy Age: 18 45 years CYP2D6 phenotyped as extensive metabolizer CYP2C19 phenotyped as extensive metabolizer Alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Healthy subjects</keyword>
</DOC>